NuVision Biotherapies
Nottingham, United Kingdom · Biotechnology, Health Care, Manufacturing · 24 employees
NuVisio® is a biotechnology research and development spin out company from the University of Nottingham. NuVision® aims to develop innovative high quality and cost effective ophthalmology and wound care regenerative therapies.
Funding history
- Funding Round — $4.8M — Feb 2026
- Series seed — $1.1M — Mar 2023
Recent signals
- May 26, 2026: NuVision Biotherapies Appoints Tim Precious as Chief Executive Officer
- Feb 05, 2026: Raised $4.8M
- Mar 09, 2023: Raised $1.1M in Series seed
See plans & pricing → Track NuVision Biotherapies’s funding, hiring, and signals — with verified contacts — on Fundz.